Saama launches COVID-19 data collaboration

By Jenni Spinner contact

- Last updated on GMT

Image: Getty/AlexRatha
Image: Getty/AlexRatha

Related tags: COVID-19, Coronavirus, Saama Technologies, Data management, Clinical trial

The company’s EndPandemic National Data Consortium aims to integrate data from clinical trials to accelerate development of a cure for the virus.

Saama Technologies is offering up its artificial intelligence (AI) powered Life Science Analytics Cloud (LSAC) technology platform to help establish the consortium. The purpose is to bring together data from both current and future studies to slash the time required to discover a cure by as much as 50%.

According to the company, the LSAC platform will enable researchers to visualize, analyze and interrogate across all available programs.

Accelerating a cure

Suresh Katta, Saama Technologies CEO and founder, told Outsourcing-Pharma that LSAC is a unique technology tool that offers authoritative oversight of clinical studies, to help reduce the time, cost and complexity of the drug development process.

It seamlessly connects, ingests, integrates, and harmonizes data from disparate clinical study streams coming from most of the source systems (EDC, CTMS, eTMF, IVR, Safety and others) globally across patients, sites, and regions and CROs​,” Katta explained.

The underlying analytics platform provides solutions to tackle a variety of business applications for pharma in clinical development across study feasibility, clinical ops, data management, biostat, and medical review/monitoring functions​,” he added.

Katta also told us the “barrier-busting collaboration” made possible by the consortium will help bring together organizations already working on solutions to the pandemic.

Currently there is a lot of great research going on in the world to help mitigate the pandemic; multiple biopharmaceutical companies and respected organizations are embarking on clinical programs to repurpose existing interventions or discover new therapeutic options​,” he said. “The consortium will establish a secure environment for biopharmaceutical companies, academic researchers, and healthcare organizations to combine their data for analysis​.”

Further, Katta said, the more scientific minds joining the collective, the better.

We challenge all scientific personnel and technology companies to join the EndPandemic National Data Consortium to work together during this crisis to pool relevant data to find treatments—and hopefully a cure—for SARS-CoV-2​.”

Collaboration is essential

David Shulkin, ninth secretary of the US Department of Veterans Affairs, said it is vital for companies to collaborate and share data to help come up with viable treatments for COVID-19 in a timely manner.

"We won't find rapid solutions for the SARS-CoV-2 pandemic with our data remaining so fragmented​," he said. “To adequately address this pandemic, we must share data from clinical studies across the research, healthcare, and pharma communities​.”

Shulkin added, “By having comprehensive datasets and deep data analytics we will have the opportunity to make great progress​.”

Any companies or organizations interested in participating in the EndPandemic National Data Consortium in order to collaborate on solutions and accelerate development of treatments should reach out to Saama Technologies at 888.970.3550.

Related news

Show more

Related products

show more

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars